54 studies found for:    "hereditary paraganglioma-pheochromocytoma" OR "Paraganglioma"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Suspended Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma
Conditions: Extra-adrenal Paraganglioma;   Metastatic Pheochromocytoma;   Paraganglioma;   Recurrent Pheochromocytoma
Interventions: Drug: pazopanib hydrochloride;   Other: laboratory biomarker analysis
2 Recruiting Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
Conditions: Paraganglioma;   Pheochromocytoma
Intervention: Drug: Sunitinib
3 Terminated Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention:
4 Active, not recruiting A Study Evaluating Ultratrace Iobenguane I 131(MIBG)in Patients With Malignant Pheochromocytoma/Paraganglioma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Radiation: Ultratrace Iobenguane I131
5 Not yet recruiting Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma
Conditions: Phaeochromocytoma;   Paraganglioma
Interventions: Drug: Vandetanib;   Radiation: 131I-mIBG
6 Unknown  Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: Ultratrace Iobenguane (MIBG) I 131
7 Available Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Conditions: Neuroblastoma;   Pheochromocytoma;   Paraganglioma
Intervention: Radiation: I-131 MIBG
8 Completed ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
Conditions: Pheochromocytoma;   Paraganglioma;   Carcinoid
Intervention: Drug: Ultratrace iobenguane I 131
9 Recruiting Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: Axitinib (AG-013736)
10 Active, not recruiting Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation
Conditions: Paragangliomas;   Pheochromocytomas
Intervention: Other: PET-CT
11 Recruiting Dovitinib in Neuroendocrine Tumors
Conditions: Advanced Metastatic Paraganglioma;   Advanced Metastatic Pheochromocytoma;   Recurrent Paraganglioma;   Recurrent Pheochromocytoma;   Unresectable Paraganglioma;   Unresectable Pheochromocytoma
Intervention: Drug: Dovitinib
12 Recruiting First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma
Condition: Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)
Interventions: Drug: Sunitinib;   Drug: Placebo
13 Completed Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma
Conditions: Pheochromocytoma;   Paraganglioma;   Essential Hypertension
Interventions: Other: plasma EM66 & CgA levels assessment;   Other: usual follow up with regular EM66 & Cga levels assessment
14 Unknown  RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid
Conditions: Pheochromocytoma;   Extra-Adrenal Paraganglioma;   Non-functioning Carcinoid
Intervention: Drug: RAD001
15 Unknown  Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers
Conditions: Paraganglioma;   Pheochromocytoma
Intervention: Procedure: diagnosis methods
16 Unknown  Expanded Access Protocol Using I131-MIBG
Conditions: Neuroblastoma;   Pheochromocytoma;   Paraganglioma
Intervention: Radiation: I-131 MIBG
17 Active, not recruiting Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Conditions: Extensive Stage Small Cell Lung Cancer;   Hereditary Paraganglioma;   Male Breast Cancer;   Malignant Paraganglioma;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Pheochromocytoma;   Pancreatic Polypeptide Tumor;   Recurrent Breast Cancer;   Recurrent Cervical Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Neuroendocrine Carcinoma of the Skin;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pheochromocytoma;   Recurrent Prostate Cancer;   Recurrent Renal Cell Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Uterine Sarcoma;   Regional Gastrointestinal Carcinoid Tumor;   Regional Pheochromocytoma;   Stage III Cervical Cancer;   Stage III Endometrial Carcinoma;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage III Ovarian Epithelial Cancer;   Stage III Ovarian Germ Cell Tumor;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Neuroendocrine Carcinoma of the Skin;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Uterine Sarcoma;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer;   Thyroid Gland Medullary Carcinoma
Interventions: Drug: temsirolimus;   Drug: vinorelbine ditartrate
18 Available Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG)
19 Completed A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Radiation: 131I-MIBG
20 Recruiting Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies
Conditions: Neuroendocrine Tumor;   Paraganglioma;   Carcinoid Tumors;   Neuroblastoma
Intervention: Drug: DOTA-TOC PET/CT

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years